Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | KDM5A | P29375 | 3/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788705 | 0.98 | CYP1A2 (0.43) | CYP1A2HPGDP2RX7SIGMAR1KDM5A | |
| SCHEMBL25192919 | 0.96 | CYP1A2 (0.43) | CYP1A2HPGDP2RX7SIGMAR1KDM5A | |
| SCHEMBL384147 | 0.94 | KDM5A (0.50) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL9061840 | 0.92 | KDM5A (0.53) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL9089300 | 0.92 | KDM5A (0.53) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL19612642 | 0.92 | KDM5A (0.53) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL6519311 | 0.89 | KDM5A (0.51) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL6521504 | 0.89 | KDM5A (0.51) | CYP1A2HPGDSIGMAR1KDM5APHF8 | |
| SCHEMBL1595294 | 0.86 | HPGD (0.53) | CYP1A2HPGDP2RX7EPHX1NPC1 | |
| SCHEMBL209174 | 0.86 | HPGD (0.53) | CYP1A2HPGDP2RX7EPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025044765-A1 | OXIME ESTER COMPOUND, PHOTORESIST, AND USE THEREOF | 北京云基科技股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024233750-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118451059-A | Ionizable cationic lipids for RNA delivery | 阿克丘勒斯治疗公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-0569386-B1 | BRIDGED CYCLIC KETAL DERIVATIVES | GLAXO GROUP LTD (GB) | 1996-09-25 | — | — | EP | disclosed |
| US-5510375-A | VIRICIDES TREATING INFECTION CAUSED BY HUMAN IMMUNODEFICIENCY VIRUS AND AIDS | WARNER-LAMBERT COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| EP-0569386-A1 | BRIDGED CYCLIC KETAL DERIVATIVES. | GLAXO GROUP LTD (GB) | 1993-11-18 | — | — | EP | disclosed |
| EP-0497091-A1 | Bridged cyclic ketal derivatives | GLAXO GROUP LIMITED (GB) | 1992-08-05 | — | — | EP | disclosed |
| WO-1992012159-A1 | BRIDGED CYCLIC KETAL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-07-23 | — | — | WO | disclosed |
| EP-0447188-A2 | 7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases | E.R. SQUIBB & SONS, INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| EP-0403090-A1 | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4977174-A | Anticoagulants, antischemic agents | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | disclosed |
| US-4108857-A | CNS DEPRESSANTS, ANALGESICS, PSYCHOMOTOR ACTION | STERLING DRUG INC. (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | CYP1A2 4491/4885HPGD 4518/4885P2RX7 3817/4885 |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | CYP1A2 4491/4885HPGD 4518/4885P2RX7 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.